Oncolytic viro-chemotherapy exhibits antitumor effect in laryngeal squamous cell carcinoma cells and mouse xenografts

References

• Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328(3):184–194. doi:10.1056/NEJM1993012132803068417385
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67(1):31–50. doi:10.3322/caac.2138627898173
   PubMed Web of Science ®Google Scholar
• Kiang A, Yu MA, Ongkeko WM. Progress and pitfalls in the identification of cancer stem cell-targeting therapies in head and neck squamous cell carcinoma. Curr Med Chem. 2012;19(35):6056–6064. 22963569
   PubMed Web of Science ®Google Scholar
• Jiao J, Qin Z, Li S, Liu H, Lu Z. Potential role of Notch1 signaling pathway in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell cycle arrest, cell apoptosis, and cell migration. Oncol Rep. 2009;22(4):815–823. 19724860
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99–102. doi:10.1038/nature1035821886163
   PubMed Web of Science ®Google Scholar
• He G, Lei W, Wang S, et al. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. J Cancer Res Clin Oncol. 2012;138(4):657–670. doi:10.1007/s00432-011-1138-222237452
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu T, Huang P, et al. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget. 2015;6(15):13564–13578. doi:10.18632/oncotarget.376925980438
   PubMedGoogle Scholar
• Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics. 2009;6(3):558–569. doi:10.1016/j.nurt.2009.04.01119560745
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. Chapter three–Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res. 2012;115:69–92. doi:10.1016/B978-0-12-398342-8.00003-323021242
   PubMed Web of Science ®Google Scholar
• Li J, Bonifati S, Hristov G, et al. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med. 2013;5(10):1537–1555. doi:10.1002/emmm.20130279624092664
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhang X, Ma B, et al. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer. Cancer Gene Ther. 2016;23(6):168–177. doi:10.1038/cgt.2016.1127080225
   PubMed Web of Science ®Google Scholar
• Huang F, Wang BR, Wu YQ, Wang FC, Zhang J, Wang YG. Oncolytic viruses against cancer stem cells: a promising approach for gastrointestinal cancer. World J Gastroenterol. 2016;22(35):7999–8009. doi:10.3748/wjg.v22.i35.799927672294
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Zloza A, Kaufman HL. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs Today (Barc). 2015;51(9):549–558. doi:10.1358/dot.2015.51.9.238304426488034
   PubMed Web of Science ®Google Scholar
• Ma B, Wang Y, Zhou X, et al. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin. J Cancer Res Clin Oncol. 2015;141(3):419–429. doi:10.1007/s00432-014-1835-825240826
   PubMed Web of Science ®Google Scholar
• Lei W, Liu HB, Wang SB, et al. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model. Acta Pharmacol Sin. 2013;34(4):531–540. doi:10.1038/aps.2012.19623503473
   PubMed Web of Science ®Google Scholar
• Zhang X, Meng S, Zhang R, et al. GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells. Oncotarget. 2016;7(20):29346–29358. doi:10.18632/oncotarget.883027121064
   PubMedGoogle Scholar
• Liu T, Han HF, Bu-Yun MA, Yang YQ, Zhuo LY. Novel synergistic anti-tumor effects of DOX with oncolytic adenovirus ZD55-TRAIL on hepatocellular carcinoma cells. China Biotechnol. 2014;34(2):26–33.
   Google Scholar
• Quirin C, Mainka A, Hesse A, Nettelbeck DM. Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int J Cancer. 2007;121(12):2801–2807. doi:10.1002/ijc.2305217724714
   PubMed Web of Science ®Google Scholar
• Kaliberova LN, Krendelchtchikova V, Harmon DK, et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther. 2009;16(10):794–805. doi:10.1038/cgt.2009.2319363468
   PubMed Web of Science ®Google Scholar
• Kangasniemi L, Parviainen S, Pisto T, et al. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. Int J Cancer. 2012;131(1):253–263. doi:10.1002/ijc.2637021834073
   PubMed Web of Science ®Google Scholar
• Song X, Wang H, Jia R, et al. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells. Int J Mol Sci. 2012;13(9):10736–10749. doi:10.3390/ijms13091073623109819
   PubMed Web of Science ®Google Scholar
• Wang SB, Tan Y, Lei W, et al. Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect. Hum Gene Ther. 2012;23(9):992–1002. doi:10.1089/hum.2011.15922530834
   PubMed Web of Science ®Google Scholar
• Komdeur R, Meijer C, Van Zweeden M, et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol. 2004;25(3):677–684. 15289869
   PubMed Web of Science ®Google Scholar
• Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25(21):3069–3075. doi:10.1200/JCO.2006.08.404617634485
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1994;22(84):27–55. doi:10.1016/0065-2571(84)90007-4
   Google Scholar
• Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5(1):85–91. 422420
   PubMed Web of Science ®Google Scholar
• Niu C, Bao H, Tolstykh T, et al. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Antivir Ther. 2010;15(3):401–412. doi:10.3851/IMP154120516559
   PubMed Web of Science ®Google Scholar
• Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett. 2007;254(2):178–216. doi:10.1016/j.canlet.2007.02.00217383089
   PubMed Web of Science ®Google Scholar
• Zhao L, Gu J, Dong A, et al. Potent antitumor activity of oncolytic adenovirus expressing mda- 7/IL-24 for colorectal cancer. Hum Gene Ther. 2005;16(7):845–858. doi:10.1089/hum.2005.16.84516000066
   PubMed Web of Science ®Google Scholar
• Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem. 2007;304(1–2):315–323. doi:10.1007/s11010-007-9514-617577631
   PubMed Web of Science ®Google Scholar
• Qi R, Gu J, Zhang Z, et al. Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. Cancer Gene Ther. 2007;14(1):82–90. doi:10.1038/sj.cgt.770099217008933
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5(2):157–163. doi:10.1038/55179930862
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Pintzas A. The TRAIL of oncogenes to apoptosis. Biofactors. 2013;39(4):343–354. doi:10.1002/biof.111223813857
   PubMed Web of Science ®Google Scholar
• Dai Y, Liu M, Tang W, et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer. 2009;9(392). doi:10.1186/1471-2407-9-392.
   Google Scholar
• Reeh M, Bockhorn M, Gorgens D, et al. Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109(7):1848–1858. doi:10.1038/bjc.2013.50924022195
   PubMed Web of Science ®Google Scholar
• Fillastre JP, Raguenez-Viotte G. Cisplatin nephrotoxicity. Toxicol Lett. 1989;46(1–3):163–175. 2650023
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3(6):673–682. 8777713
   PubMed Web of Science ®Google Scholar
• Zhao T, Rao XM, Xie X, et al. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res. 2003;63(12):3073–3078. 12810631
   PubMed Web of Science ®Google Scholar
• Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 2001;8(2):89–98. doi:10.1038/sj.gt.330137711313778
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther. 2010;18(2):243–250. doi:10.1038/mt.2009.26619935777
   PubMed Web of Science ®Google Scholar
• Ding X, Ding J, Ning J, et al. Circulating microRNA-122 as a potential biomarker for liver injury. Mol Med Rep. 2012;5(6):1428–1432. doi:10.3892/mmr.2012.83822427142
   PubMed Web of Science ®Google Scholar
• Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–593. doi:10.1016/j.ygyno.2010.07.02120801493
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhu C, Zhu L, et al. Oncogenicity of the transcription factor SOX8 in hepatocellular carcinoma. Med Oncol. 2014;31(4):918. doi:10.1007/s12032-014-0374-024643625
   PubMed Web of Science ®Google Scholar